title: [Tuberculosis in patients with lymphoproliferative diseases].
abstract: OBJECTIVE
  To study the clinical manifestations, diagnosis, and treatment of lymphoproliferative diseases (LPD) concurrent with tuberculosis.
  
  
  METHODS
  In 1990 to 2013, the Hematology Research Center, Ministry of Health of Russia, followed up 4422 patients with LPD. Lymphomas and leukemias were diagnosed using the universally protocols. Tuberculosis was verified by the results of a comprehensive examination involving the histological study of biopsy specimens.
  
  
  RESULTS
  Tuberculosis was identified in 85 (2%) patients with LPD. According to the nosological entity, the tuberculosis detection rates were 3% (40/1350) in Hodgkin lymphoma (HL), 1.2% (20/1627) in aggressive lymphomas, 1.4% (16/1136) in mature cell lymphomas and chronic lymphocytic leukemia, and 2.9% (9/309) in hairy cell leukemia. In accordance with its site, pulmonary tuberculosis was 73%; extrapulmonary tuberculosis, 14%; generalized tuberculosis, 12%. In pulmonary tuberculosis, its disseminated and focal involvements were found in 71 and 18% of cases, respectively. Tuberculosis was detected in 43% of the patients with HL in remission; it occurred only in other hemoblastoses in its active phase. When tuberculosis and LPD were simultaneously found, both diseases were concurrently treated. If the chemotherapy of LPD was effective, tuberculosis was cured in all the patients.
  
  
  CONCLUSIONS
  Patients with LPD are a group at increased risk for tuberculosis. The diagnosis of recurrent LPD must be histologically proven. When tuberculosis and LPD are simultaneously found, both diseases should be concurrently treated.
authors.forename: L S
authors.initials: LS
authors.lastname: Al-Radi
authors.forename: T N
authors.initials: TN
authors.lastname: Moiseeva
authors.forename: N G
authors.initials: NG
authors.lastname: Chernova
authors.forename: N N
authors.initials: NN
authors.lastname: Sharkunov
authors.forename: O V
authors.initials: OV
authors.lastname: Margolin
authors.forename: I V
authors.initials: IV
authors.lastname: Shitareva
authors.forename: E A
authors.initials: EA
authors.lastname: Baryakh
authors.forename: G A
authors.initials: GA
authors.lastname: Klyasova
authors.forename: L S
authors.initials: LS
authors.lastname: Roshchina
authors.forename: I E
authors.initials: IE
authors.lastname: Kostina
authors.forename: S K
authors.initials: SK
authors.lastname: Kravchenko
authors.forename: A V
authors.initials: AV
authors.lastname: Pivnik
authors.forename: A I
authors.initials: AI
authors.lastname: Vorobiov
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001706:Biopsy; D006801:Humans; D007938:Leukemia / Q000150:complications / Q000453:epidemiology* / Q000473:pathology; D008223:Lymphoma / Q000150:complications / Q000453:epidemiology* / Q000473:pathology; D012307:Risk Factors; D012426:Russia / Q000453:epidemiology; D014376:Tuberculosis / Q000453:epidemiology* / Q000209:etiology / Q000628:therapy; D014397:Tuberculosis, Pulmonary / Q000453:epidemiology / Q000209:etiology / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents